NCT00383474View on ClinicalTrials.gov

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal DifferentiationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAdult ErythroleukemiaAdult Pure Erythroid LeukemiaBlastic PhaseRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent DiseaseUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

Bortezomib

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Tipifarnib

Given orally

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00383474 - Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | Biotech Hunter | Biotech Hunter